Lymphoma | Norton Healthcare

Indication: Lymphoma

A Phase 1 Study of TG-1501 in Subjects with Relapsed or Refractory Lymphoma

Relapsed or Refractory

Line of Therapy: relapsed or refractory classical Hodgkin lymphoma (cHL) or B-cell non-Hodgkin lymphoma (NHL).

Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: TG Therapeutics, Inc

Learn more at

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.